News

Draximage has granted GE Healthcare the exclusive right to market, distribute and sell its generic Draximage Sestamibi in the US market through its US and Canadian radiopharmacy network,

The study will evaluate approximately 340 patients with mild to moderate Alzheimer’s disease. Approximately 65 sites in North America are expected to participate in the program. The study

Under the terms of the new agreement Lundbeck obtains global exclusive rights to Desmoteplase (now including North America) with full control of development and commercialization of the drug

The financial terms of the license agreement consist of an up-front license fee payment to be made by Alphatec to Progressive; testing, design, regulatory and sales milestone payments

Xibrom is a topical non-steroidal anti-inflammatory compound for the treatment of ocular inflammation and pain. Xibrom, approved in 2005, is the first and only FDA-approved twice-daily NSAID for

The trial will include up to nine boys with Duchenne muscular dystrophy (DMD), each of whom will receive a single intramuscular (IM) administration of the drug. Two to

The approval is primarily based on the results of two randomized, controlled, multi-center clinical trials in adult patients: Champion and Reveal. In both trials, the signs and symptoms

In the primary analysis, there was no statistically significant difference in the progression-free survival (PFS) of patients receiving MyVax personalized immunotherapy compared to patients receiving the control substance.

On May 24, 2007 Naviscan filed suit against Dilon in the US District Court of California for possible patent infringement of six US patents directed to technology for